1333317-69-3

Basic information

• Product Name: N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine
• Synonyms: N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine
• CAS NO: 1333317-69-3
• Molecular Weight: 269.19
• Mol File: 1333317-69-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine(1333317-69-3)
• EPA Substance Registry System: N-(1-(3,5-bis(trifluoromethyl) phenyl)ethylidene)methanamine(1333317-69-3)

Safety Data

• Hazardous Substances Data: 1333317-69-3(Hazardous Substances Data)

Upstream product

• 30071-93-3 3,5-bis(trifluoromethyl)phenyl methyl ketone 
• 74-89-5 methylamine 

Downstream Products

• 334476-68-5 2-(S)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide 
• 334477-60-0 [(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl](methyl)amine 
• 511256-36-3 (S)-1-(3,5-bis(trifluoromethyl)phenyl)-N-methylethanamine 
• 1333317-71-7 (S)-N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-N-methylacetamide 
• 1333317-70-6 (R)-N-(1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-N-methylacetamide 

Relevant articles and documents

Synthesis of the NK1 receptor antagonist GW597599. Part 1: development of a scalable route to a key chirally pure arylpiperazine

GW5975991 is a novel NK-1 antagonist currently under investigation for the treatment of CNS disorders and emesis. The initial synthetic route devised from the medicinal chemistry one, used several hazardous reagents, gave low yields, and produced high lev

CATALYST COMPOUNDS

The present invention relates to compounds, particularly but not exclusively, compounds for use as catalysts, methods for producing said compounds and the use of said compounds as catalysts in catalytic processes including, but not limited to, the asymmetric reduction of imine and enamine compounds and/or the reductive amination of ketone compounds. The compounds have the formula 1 wherein: R1, R2, R3, R4 and R5 are each separately selected from the group consisting of hydrogen, alkyl and aryl; X is oxygen or sulfur; W is selected from the group consisting of – OR18,–SR18, –NR19R20, –PR19R20 where R18 is alkyl or aryl, and R19 and R20 are each separately selected from the group consisting of hydrogen, alkyl and aryl; and Z has the formula 2 wherein: R6 and R7 are each separately selected from the group consisting of hydrogen, alkoxy, nitro, halogen, alkyl and aryl, or R6 and R7 are linked to form a cyclic group; and Y is oxygen, sulfur or NR10 in which R10 is selected from the group consisting of hydrogen, alkyl and aryl.

Synthesis of the NK1 receptor antagonist GW597599. Part 3: Development of a scalable route to a key chirally pure arylpiperazine urea, a happy end

GW597599 1 is a novel NK-1 antagonist currently under investigation for the treatment of central nervous system disorders and emesis. The initial chemical development synthetic route, derived from the one used by medicinal chemistry, involved several haza